Molybdenum and Copper Excretion Guidelines

Introduction to Molybdenum Therapy

The European Society for Clinical Nutrition and Metabolism recommends molybdenum in the form of tetrathiomolybdate for treating copper overload in Wilson's disease, specifically at a dose of 120 mg/day divided into 6 doses of 20 mg each 1, 2, 3, 4, 5, 6, 7

Molybdenum increases fecal copper excretion by forming complexes that prevent copper absorption and enhance biliary excretion of absorbed copper, although the primary reference for this mechanism is not provided, high concentrations of molybdenum can induce copper deficiency in animals through competitive mechanisms, demonstrating its potency in reducing copper bioavailability 3, 4, 6

The American Association for the Study of Liver Diseases recommends D-penicillamine (250-500 mg/day initially) as the first-line chelation therapy for Wilson's disease, with tetrathiomolybdate serving as an alternative copper-reducing agent when standard chelation is not suitable 1, 2, 8, 9

The upper tolerable limit for molybdenum is 2 mg/day for general supplementation, with toxicity reported at 300-800 mg/day, but therapeutic doses of tetrathiomolybdate (120 mg/day) for Wilson's disease have been used safely under medical supervision 3, 4, 5, 6, 7, 10
Regular monitoring of both copper and liver function is essential when using molybdenum therapy for copper overload, with monitoring every 6-12 months 8

At the upper tolerable limit of 2 mg/day, molybdenum can induce copper deficiency in susceptible individuals, with high concentrations causing copper deficiency in animals through competitive mechanisms, according to Clinical Nutrition 11
For Wilson's disease treatment, a dose of 120 mg/day of tetrathiomolybdate is used, representing a dose 60-fold higher than the upper tolerable limit, but is used safely under medical supervision, as recommended by Clinical Nutrition 11

Intakes of 10-15 mg/day of molybdenum have been associated with clinical manifestations including aching joints and gout-like symptoms in areas with extremely high soil molybdenum content, as reported by Clinical Nutrition 11

The National Institute of Nutrition recommends copper monitoring for patients on long-term parenteral nutrition, post-bariatric surgery patients, those with unexplained neuropathy, or patients on therapeutic molybdenum doses 12
Individuals with inadequate dietary copper intake, defined as less than 1-3 mg/day, are at higher risk of copper deficiency with molybdenum supplementation, according to the Clinical Nutrition guidelines 12
Post-bariatric surgery patients are at increased risk of copper deficiency due to impaired copper absorption, as stated by the Clinical Nutrition guidelines 12